Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953074 | 1.00 | HSD17B10 (0.49) | HSD17B10ALOX15LMNAAKR1C3POLB | |
| SCHEMBL29953330 | 0.82 | KEAP1 (0.55) | POLBMAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL3195999 | 0.82 | KEAP1 (0.55) | POLBMAPTL3MBTL1MEN1KMT2A | |
| Boric Acid SCHEMBL6314068 | 0.81 | AKR1C3 (0.65) | HSD17B10ALOX15LMNAAKR1C3POLB | |
| SCHEMBL9424119 | 0.81 | LMNA (0.62) | HSD17B10ALOX15LMNAAKR1C3POLB | |
| SCHEMBL16568999 | 0.80 | KEAP1 (0.59) | POLBMAPTL3MBTL1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL29952686 | 0.80 | KEAP1 (0.53) | POLBMAPTL3MBTL1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL29953158 | 0.78 | KEAP1 (0.57) | LMNAPOLBMAPTL3MBTL1MEN1 | |
| SCHEMBL4008990 | 0.78 | ADRA2C (0.63) | HSD17B10LMNAPOLBMAPTL3MBTL1 | |
| SCHEMBL2454191 | 0.77 | POLB (0.39) | HSD17B10ALOX15LMNAAKR1C3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507262-B2 | Compositions for oxidatively dyeing keratin fibers and methods for using such compositions | THE PROCTER & GAMBLE COMPANY (US) | 2009-03-24 | — | — | US | claimed |
| EP-2018146-A2 | COMPOSITIONS FOR OXIDATIVELY DYEING KERATIN FIBERS AND METHODS FOR USING SUCH COMPOSITIONS | The Procter and Gamble Company (US) | 2009-01-28 | — | — | EP | claimed |
| US-20070209123-A1 | Compositions for oxidatively dyeing keratin fibers and methods for using such compositions | THE PROCTER & GAMBLE COMPANY | 2007-09-13 | — | — | US | claimed |
| WO-2007102126-A2 | COMPOSITIONS FOR OXIDATIVELY DYEING KERATIN FIBERS AND METHODS FOR USING SUCH COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2007-09-13 | — | — | WO | claimed |
| CN-114008049-B | EGFR inhibitors for cancer treatment | 豪夫迈·罗氏有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-117924198-A | Bioactive compounds and methods thereof | 上海科因生物医药科技有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-116635028-A | Modulators of c-MYC mRNA translation and their use in the treatment of cancer | 艾尼莫生物科技公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-110357863-B | Triazine double aromatic ring derivative epidermal growth factor inhibitor and preparation method and application thereof | 药雅科技(上海)有限公司 | 2023-04-14 | — | — | CN | disclosed |
| US-11608334-B2 | Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof | The National Institutes of Pharmaceutical R&D Co., Ltd. (CN) | 2023-03-21 | — | — | US | disclosed |
| US-11555026-B2 | AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-01-17 | — | — | US | disclosed |
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. (US) | 2022-12-15 | — | — | US | disclosed |
| CN-110713489-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-05-31 | — | — | CN | disclosed |
| EP-1937678-A1 | HIV INTEGRASE INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007102126-A2 | COMPOSITIONS FOR OXIDATIVELY DYEING KERATIN FIBERS AND METHODS FOR USING SUCH COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070209123-A1 | Compositions for oxidatively dyeing keratin fibers and methods for using such compositions | THE PROCTER & GAMBLE COMPANY | 2007-09-13 | — | — | US | disclosed |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
| WO-2007080401-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007065664-A2 | PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXYLIC ACIDS AS EPHB AND VEGFR2 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065940-A1 | ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES | LABORATOIRES SERONO S.A. (CH) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007039218-A1 | HIV INTEGRASE INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11555026-B2 | AHR inhibitors and uses thereof | AHR, ARNT, AIPL1 | HSD17B10 291/4885ALOX15 290/4885LMNA 4108/4885 |
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | HSD17B10 3992/4885ALOX15 3114/4885LMNA 2835/4885 |
| US-11608334-B2 | Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof | BTK, SYK, ITK | HSD17B10 3504/4885ALOX15 532/4885LMNA 4215/4885 |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GOT2, PC, CYP11B2 | HSD17B10 132/4885ALOX15 2156/4885LMNA 1948/4885 |
| US-20070209123-A1 | Compositions for oxidatively dyeing keratin fibers and methods for using such compositions | KRT18, AKR7A2, AKR1C4 | HSD17B10 1179/4885ALOX15 2949/4885LMNA 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.